InflaRx N.V.

NasdaqGS:IFRX Voorraadrapport

Marktkapitalisatie: US$129.5m

InflaRx Beheer

Beheer criteriumcontroles 2/4

De CEO InflaRx is Niels Riedemann, benoemd in Jan2007, heeft een ambtstermijn van 17.83 jaar. bezit rechtstreeks 1.82% van de aandelen van het bedrijf, ter waarde $ 2.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 5.5 jaar.

Belangrijke informatie

Niels Riedemann

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO17.8yrs
Eigendom CEO1.8%
Management gemiddelde ambtstermijn3.9yrs
Gemiddelde ambtstermijn bestuur5.5yrs

Recente managementupdates

Recent updates

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Jun 25
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Dec 23
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 17
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Mar 28
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Nov 30
Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16
Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15
Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01
We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02
Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (51 yo)

17.8yrs

Tenure

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Niels Riedemann
Co-Founder17.8yrsgeen gegevens1.82%
$ 2.4m
Renfeng Guo
Co-Founder17.8yrsgeen gegevens2.99%
$ 3.9m
Thomas Taapken
Chief Financial Officer4.1yrsgeen gegevens0.0059%
$ 7.7k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance1.6yrsgeen gegevensgeen gegevens
Camilla Chong
Chief Medical Officer1.3yrsgeen gegevensgeen gegevens
Jan Medina
Head of Investor Relations & VPless than a yeargeen gegevensgeen gegevens
Christian Schmid
VP and Head of Legal Affairs & General Counselno datageen gegevensgeen gegevens
Nicole Bertsch
Senior Director & Head of Human Resources3.7yrsgeen gegevensgeen gegevens
Maria Habel
VP, Head of Preclinical R&D and QC11.8yrsgeen gegevensgeen gegevens
Bruce Burnett
VP & Head of Medical Affairsno datageen gegevensgeen gegevens
Kofi Boaten
Senior Director and Head of Supply Quality & Clinical Trial Suppliesno datageen gegevensgeen gegevens
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno datageen gegevensgeen gegevens

3.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Niels Riedemann
Co-Founderno datageen gegevens1.82%
$ 2.4m
Renfeng Guo
Co-Founderno datageen gegevens2.99%
$ 3.9m
Nicolas Fulpius
Independent Chairman of the Board17.8yrsgeen gegevens0.79%
$ 1.0m
K. Reinhart
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
P. Ward
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Brudnick
Independent Non-Executive Director5.5yrsgeen gegevens0.085%
$ 110.0k
Hege Hellstrom
Non-Executive Director1.6yrsgeen gegevensgeen gegevens
Mark Kubler
Independent Non-Executive Director9.8yrsgeen gegevens1.63%
$ 2.1m
Anthony Gibney
Independent Non-Executive Director3.5yrsgeen gegevens0.017%
$ 22.0k

5.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).